Does Proton Pump Inhibitors Decrease the Efficacy of Palbociclib and Ribociclib in Patients with Metastatic Breast Cancer?
<i>Background and Objectives:</i> This investigation aimed to determine the impacts of concurrent proton pump inhibitors (PPIs) on progression-free survival (PFS) in patients with hormone receptor-positive and HER2-negative metastatic breast cancer managed with palbociclib or ribociclib...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-03-01
|
| Series: | Medicina |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1648-9144/59/3/557 |
| _version_ | 1797610255336603648 |
|---|---|
| author | Hatice Odabas Akif Dogan Melike Ozcelik Sedat Yildirim Ugur Ozkerim Nedim Turan Mahmut Emre Yildirim Mahmut Gumus |
| author_facet | Hatice Odabas Akif Dogan Melike Ozcelik Sedat Yildirim Ugur Ozkerim Nedim Turan Mahmut Emre Yildirim Mahmut Gumus |
| author_sort | Hatice Odabas |
| collection | DOAJ |
| description | <i>Background and Objectives:</i> This investigation aimed to determine the impacts of concurrent proton pump inhibitors (PPIs) on progression-free survival (PFS) in patients with hormone receptor-positive and HER2-negative metastatic breast cancer managed with palbociclib or ribociclib as either the initial or subsequent line of therapy option. <i>Materials and Methods:</i> In this retrospective study, patients were classified as “concurrent PPIs” if PPIs were given for at least two-thirds of the palbociclib or ribociclib therapy period, and “no concurrent PPIs” if no PPIs were given during the period of palbociclib or ribociclib therapy. Each patient was also classified as endocrine-sensitive or endocrine-resistant according to the duration of previous endocrine responses. “Concurrent PPIs” and “no concurrent PPIs” groups were compared with each other in terms of PFS. This comparison was performed for both ribociclib and palbociclib groups. <i>Results</i>: The research included 220 patients in total. The PFS of 57 patients on palbociclib using concomitant PPIs was 14.4 months. Among 63 patients using palbociclib without concomitant PPIs, the PFS was 15.8 months. No statistically significant difference was found with PPI use (<i>p</i> = 0.82). Among 29 patients using ribociclib concurrently with PPIs, the PFS was 22.4 months. Among 71 patients using ribociclib without PPIs, the PFS was 20.2 months. No statistically significant difference was found with PPI use (<i>p</i> = 0.40). <i>Conclusion</i>: The results of our investigation showed that concomitant use of the most commonly used PPIs in the study (lansoprazole, pantoprazole, and esomeprazole) with palbociclib or ribociclib did not have any detrimental effects on PFS. Where appropriate, PPIs can be used concurrently with palbociclib and ribociclib. However, the effect of PPIs on cycling-dependent kinase 4/6 inhibitors deserves further investigation. |
| first_indexed | 2024-03-11T06:11:59Z |
| format | Article |
| id | doaj.art-0e0b7c0de82c401fb9197cf40efeed4d |
| institution | Directory Open Access Journal |
| issn | 1010-660X 1648-9144 |
| language | English |
| last_indexed | 2024-03-11T06:11:59Z |
| publishDate | 2023-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medicina |
| spelling | doaj.art-0e0b7c0de82c401fb9197cf40efeed4d2023-11-17T12:32:21ZengMDPI AGMedicina1010-660X1648-91442023-03-0159355710.3390/medicina59030557Does Proton Pump Inhibitors Decrease the Efficacy of Palbociclib and Ribociclib in Patients with Metastatic Breast Cancer?Hatice Odabas0Akif Dogan1Melike Ozcelik2Sedat Yildirim3Ugur Ozkerim4Nedim Turan5Mahmut Emre Yildirim6Mahmut Gumus7Department of Medical Oncology, University of Health Sciences, Kartal Dr. Lutfi Kirdar City Hospital, Istanbul 34865, TurkeyDepartment of Medical Oncology, University of Health Sciences, Kartal Dr. Lutfi Kirdar City Hospital, Istanbul 34865, TurkeyDepartment of Medical Oncology, University of Health Sciences, Umraniye Training and Research Hospital, Istanbul 34764, TurkeyDepartment of Medical Oncology, University of Health Sciences, Kartal Dr. Lutfi Kirdar City Hospital, Istanbul 34865, TurkeyDepartment of Medical Oncology, University of Health Sciences, Kartal Dr. Lutfi Kirdar City Hospital, Istanbul 34865, TurkeyDepartment of Medical Oncology, University of Health Sciences, Kartal Dr. Lutfi Kirdar City Hospital, Istanbul 34865, TurkeyDepartment of Medical Oncology, University of Health Sciences, Kartal Dr. Lutfi Kirdar City Hospital, Istanbul 34865, TurkeyDepartment of Medical Oncology, Faculty of Medicine, Istanbul Medeniyet University, Istanbul 34722, Turkey<i>Background and Objectives:</i> This investigation aimed to determine the impacts of concurrent proton pump inhibitors (PPIs) on progression-free survival (PFS) in patients with hormone receptor-positive and HER2-negative metastatic breast cancer managed with palbociclib or ribociclib as either the initial or subsequent line of therapy option. <i>Materials and Methods:</i> In this retrospective study, patients were classified as “concurrent PPIs” if PPIs were given for at least two-thirds of the palbociclib or ribociclib therapy period, and “no concurrent PPIs” if no PPIs were given during the period of palbociclib or ribociclib therapy. Each patient was also classified as endocrine-sensitive or endocrine-resistant according to the duration of previous endocrine responses. “Concurrent PPIs” and “no concurrent PPIs” groups were compared with each other in terms of PFS. This comparison was performed for both ribociclib and palbociclib groups. <i>Results</i>: The research included 220 patients in total. The PFS of 57 patients on palbociclib using concomitant PPIs was 14.4 months. Among 63 patients using palbociclib without concomitant PPIs, the PFS was 15.8 months. No statistically significant difference was found with PPI use (<i>p</i> = 0.82). Among 29 patients using ribociclib concurrently with PPIs, the PFS was 22.4 months. Among 71 patients using ribociclib without PPIs, the PFS was 20.2 months. No statistically significant difference was found with PPI use (<i>p</i> = 0.40). <i>Conclusion</i>: The results of our investigation showed that concomitant use of the most commonly used PPIs in the study (lansoprazole, pantoprazole, and esomeprazole) with palbociclib or ribociclib did not have any detrimental effects on PFS. Where appropriate, PPIs can be used concurrently with palbociclib and ribociclib. However, the effect of PPIs on cycling-dependent kinase 4/6 inhibitors deserves further investigation.https://www.mdpi.com/1648-9144/59/3/557metastatic breast cancerpalbociclibribociclibproton pump inhibitorsdrug-drug interactions |
| spellingShingle | Hatice Odabas Akif Dogan Melike Ozcelik Sedat Yildirim Ugur Ozkerim Nedim Turan Mahmut Emre Yildirim Mahmut Gumus Does Proton Pump Inhibitors Decrease the Efficacy of Palbociclib and Ribociclib in Patients with Metastatic Breast Cancer? Medicina metastatic breast cancer palbociclib ribociclib proton pump inhibitors drug-drug interactions |
| title | Does Proton Pump Inhibitors Decrease the Efficacy of Palbociclib and Ribociclib in Patients with Metastatic Breast Cancer? |
| title_full | Does Proton Pump Inhibitors Decrease the Efficacy of Palbociclib and Ribociclib in Patients with Metastatic Breast Cancer? |
| title_fullStr | Does Proton Pump Inhibitors Decrease the Efficacy of Palbociclib and Ribociclib in Patients with Metastatic Breast Cancer? |
| title_full_unstemmed | Does Proton Pump Inhibitors Decrease the Efficacy of Palbociclib and Ribociclib in Patients with Metastatic Breast Cancer? |
| title_short | Does Proton Pump Inhibitors Decrease the Efficacy of Palbociclib and Ribociclib in Patients with Metastatic Breast Cancer? |
| title_sort | does proton pump inhibitors decrease the efficacy of palbociclib and ribociclib in patients with metastatic breast cancer |
| topic | metastatic breast cancer palbociclib ribociclib proton pump inhibitors drug-drug interactions |
| url | https://www.mdpi.com/1648-9144/59/3/557 |
| work_keys_str_mv | AT haticeodabas doesprotonpumpinhibitorsdecreasetheefficacyofpalbociclibandribociclibinpatientswithmetastaticbreastcancer AT akifdogan doesprotonpumpinhibitorsdecreasetheefficacyofpalbociclibandribociclibinpatientswithmetastaticbreastcancer AT melikeozcelik doesprotonpumpinhibitorsdecreasetheefficacyofpalbociclibandribociclibinpatientswithmetastaticbreastcancer AT sedatyildirim doesprotonpumpinhibitorsdecreasetheefficacyofpalbociclibandribociclibinpatientswithmetastaticbreastcancer AT ugurozkerim doesprotonpumpinhibitorsdecreasetheefficacyofpalbociclibandribociclibinpatientswithmetastaticbreastcancer AT nedimturan doesprotonpumpinhibitorsdecreasetheefficacyofpalbociclibandribociclibinpatientswithmetastaticbreastcancer AT mahmutemreyildirim doesprotonpumpinhibitorsdecreasetheefficacyofpalbociclibandribociclibinpatientswithmetastaticbreastcancer AT mahmutgumus doesprotonpumpinhibitorsdecreasetheefficacyofpalbociclibandribociclibinpatientswithmetastaticbreastcancer |